Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.

ABSTRACT:

Background

Bevacizumab is a humanized antibody against vascular endothelial growth factor approved for treatment of recurrent glioblastoma. There is a need to discover imaging biomarkers that can aid in the selection of patients who will likely derive the most survival benefit from bevacizumab.

Methods

The aim of the study was to examine if pre- and posttherapy multimodal MRI features could predict progression-free survival and overall survival (OS) for patients with recurrent glioblastoma treated with bevacizumab. The patient population included 84 patients in a training cohort and 42 patients in a testing cohort, separated based on pretherapy imaging date. Tumor volumes of interest were segmented from contrast-enhanced T1-weighted and fluid attenuated inversion recovery im

SUBMITTER: Chang K 

PROVIDER: S-EPMC6693191 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature